China Children's Leukemia Group (CCLG)-2018-T-ALL multicenter study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027966

Enrollment

Unknown

Registered

2019-12-07

Start date

2020-01-01

Completion date

Unknown

Last updated

2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic leukemia

Interventions

Intermediate risk group:Inductive therapy (Pred+VDLD/P)+Early intensive therapy (CAML×2)+Consolidation therapy(M)+Delay intensive therapy?(VDLD+CAML)+Middle maintenance thrapy(6-MP/MTX)+Delay intensiv

High risk group:Inductive therapy (Pred+VDLD)+Early intensive therapy(CAML×2)+Consolidation therapy(HR-1, HR-2, HR-3)×2+Delay intensive therapy(VDLD+CAML)+Maintenance thrapy(6-MP+MTX/VD)

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1, Less than 18 years old; 2. The diagnosis is acute lymphoblastic leukemia (ALL), and the immunophenotype is T lymphocyte phenotype; 3. New patients.

Exclusion criteria

Exclusion criteria: 1. Secondary to immunodeficiency disease; 2. Second tumor; 3. CML zag leukemia; 4. ALL with Down 'S syndrome; 5. The glucocorticoid is used for more than one week or chemotherapy one month before in the group.

Design outcomes

Primary

Measure	Time frame
minimal residual disease;	—

Countries

China

Contacts

Public ContactWang Tianyou

Beijing Children's Hospital, Capital Medical University

wangtianyou6688@yeah.net+86 13331119559

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026